This phase II randomized trial is for patients with clinical stage II-III, ER and PR <10%,
HER2-negative invasive breast carcinoma (triple negative breast cancer) for whom adjuvant RT
is planned and pre-operative RT is deemed feasible by the treating radiation oncologist.
Subjects will be randomized into arm A or B and treatment will last for 16 weeks. Both groups
will receive Durvalumab 750mg IV Q2 weeks x 2 then a biopsy prior to durvalumab 1500mg IV Q4
weeks x 3 with paclitaxel and carboplatin IV weekly x 12. Arm B will receive radiation (24 Gy
total) starting with the second durvalumab dose every other day (8Gy per fraction) for one
week. Following treatment, subjects will receive SOC breast surgery and continue on to
physician's choices SOC treatment during the 3 year follow up period.
This study hopes to explore the impact of checkpoint blockade administration with a non-
anthracycline chemotherapy regimen plus RT on post-surgery pathologic complete response (pCR)
rate in the breast and axilla (ypT0/Tis ypN0) following 12 weeks of treatment and surgery.
1. Male/female patients with histologically confirmed invasive breast cancer, ER <10%, PR
<10% and HER2-negative for whom adjuvant RT is planned and in whom pre-operative RT is
2. Clinical stage II-III by the AJCC 8th definition, any nodal status (cT2-4N0 or
cT1-4N1-3), biopsies of clinically suspicious lymph nodes to confirm nodal status is
3. Capable of giving signed informed consent which includes compliance with the
requirements and restrictions listed in the informed consent form and in this
protocol. Written informed consent and any locally required authorization obtained
from the patient/legal representative prior to performing any protocol-related
procedures, including screening evaluations.
4. At least 18 years of age on the day of signing informed consent.
5. The participant (or legally acceptable representative if applicable) provides written
informed consent for the trial.
6. Body weight >30kg.
7. Have provided archival tumor tissue sample or newly obtained core or excisional biopsy
of a tumor lesion not previously irradiated. Formalin-fixed, paraffin embedded (FFPE)
tissue blocks are preferred to slides. Newly obtained biopsies are preferred to
8. Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.
9. Have adequate organ function as defined in the following table (Table 1). Specimens
must be collected within 10 days prior to the start of study treatment.
10. Patient is willing and able to comply with the protocol for the duration of the study
including undergoing treatment and scheduled visits and examinations including follow
11. Patients with multifocal, multicentric or bilateral breast cancer are permitted if all
suspicious foci have been biopsied and deemed "triple negative" per criterion 1.
12. A male participant must agree to use a contraception as detailed in Appendix C of this
protocol during the treatment period and for at least 6 months after the last dose of
study treatment and refrain from donating sperm during this period.
13. A female participant is eligible to participate if she is not pregnant (see Appendix
C), not breastfeeding, and at least one of the following conditions applies:
1. Not a woman of childbearing potential (WOCBP) as defined in Appendix C OR
2. A WOCBP who agrees to follow the contraceptive guidance in Appendix C during the
treatment period and for at least 6 months after the last dose of study
1. A WOCBP who has a positive urine pregnancy test within 72 hours prior to randomization
(see Appendix C). If the urine test is positive or cannot be confirmed as negative, a
serum pregnancy test will be required.
2. Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti PD L2 agent or with
an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g.,
CTLA-4, OX 40, CD137).
3. Any concurrent chemotherapy, IP, biologic, or hormonal therapy for cancer treatment.
Concurrent use of hormonal therapy for non-cancer-related conditions (e.g., hormone
replacement therapy) is acceptable.
4. Major surgical procedure within 28 days prior to the first dose of study drug.
5. History of allogenic organ transplantation.
6. Has received a live vaccine within 30 days prior to the first dose of study drug.
Examples of live vaccines include, but are not limited to, the following: measles,
mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus
Calmette-Guérin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection
are generally killed virus vaccines and are allowed; however, intranasal influenza
vaccines (eg, FluMist®) are live attenuated vaccines and are not allowed. Note:
Patients, if enrolled, should not receive live vaccine whilst receiving IP and up to
30 days after the last dose of IP.
7. Participation in another clinical study with an investigational product during the
last 4 weeks, unless it is an observational (non-interventional) clinical study or
during the follow-up period of an interventional study.
8. Current or prior use of immunosuppressive medication within 14 days before the first
dose of durvalumab. The following are exceptions to this criterion:
1. Intranasal, inhaled, topical steroids, or local steroid injections (e.g., intra
2. Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of
prednisone or its equivalent
3. Steroids as premedication for hypersensitivity reactions (e.g., CT scan
9. History of another primary malignancy except for:
1. Malignancy treated with curative intent and with no known active disease ≥5 years
before the first dose of IP and of low potential risk for recurrence
2. Adequately treated non-melanoma skin cancer or lentigo maligna without evidence
3. Adequately treated carcinoma in situ without evidence of disease
10. Known allergy or hypersensitivity to any of the study drugs or any of the study drug
11. Active or prior documented autoimmune or inflammatory disorders (including
inflammatory bowel disease [e.g., colitis or Crohn's disease], diverticulitis [with
the exception of diverticulosis], systemic lupus erythematosus, Sarcoidosis syndrome,
or Wegener syndrome [granulomatosis with polyangiitis, Graves' disease, rheumatoid
arthritis, hypophysitis, uveitis, etc]). The following are exceptions to this
1. Patients with vitiligo or alopecia
2. Patients with hypothyroidism (e.g., following Hashimoto syndrome) stable on
3. Any chronic skin condition that does not require systemic therapy
4. Patients without active disease in the last 5 years may be included but only
after consultation with the study physician
5. Patients with celiac disease controlled by diet alone
12. Has a history of (non-infectious) pneumonitis that required steroids or has current
13. Has an active infection requiring systemic therapy.
14. History of active primary immunodeficiency.
15. Known active infection including tuberculosis (clinical evaluation that includes
clinical history, physical examination and radiographic findings, and TB testing in
line with local practice), hepatitis B, hepatitis C, or human immunodeficiency virus .
Patients with a past or resolved HBV infection are eligible. Patients positive for
hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative
for HCV RNA.
16. Uncontrolled intercurrent illness, including but not limited to, ongoing or active
infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable
angina pectoris, cardiac arrhythmia, interstitial lung disease, serious chronic
gastrointestinal conditions associated with diarrhoea, or psychiatric illness/social
situations that would limit compliance with study requirement, substantially increase
risk of incurring AEs or compromise the ability of the patient to give written
17. Female patients who are pregnant or breastfeeding or male or female patients of
reproductive potential who are not willing to employ effective birth control from
screening to 90 days after the last dose of durvalumab monotherapy.
18. Prior randomization or treatment in a previous durvalumab clinical study regardless of
treatment arm assignment.
19. Stage IV (metastatic) breast cancer
20. Inflammatory breast cancer